EUVIMEDEUVIMED entdecken
Crossref

SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy

Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J Koo, Alicia K Morgans, Joseph R Osborne, Scott T Tagawa, Mary-Ellen Taplin, Oliver Sartor und 1 weitere

Journal of Nuclear Medicine · 2023-09 · 64 (9) · 1417-1423

DOI: 10.2967/jnumed.123.265952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.06.2023. Verfasst von Thomas A Hope und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is a transmembrane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansPatient SelectionRadioisotopesDipeptidesHeterocyclic Compounds, 1-RingLutetium

Substanzen

PSMA-617Prostate-Specific AntigenRadioisotopesDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
  • University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Department of Radiology, University of Washington, Seattle, Washington.
  • Department of Radiology, Brigham and Women's Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.

Zitieren

APA

Hope, T. A., Antonarakis, E. S., Bodei, L., Calais, J., Iravani, A., Jacene, H., Koo, P. J., Morgans, A. K., Osborne, J. R., Tagawa, S. T., Taplin, M. E., Sartor, O., & Morris, M. J. (2023). SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy. Journal of Nuclear Medicine, 64(9), 1417-1423. https://doi.org/10.2967/jnumed.123.265952

Vancouver

Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, et al. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy. Journal of Nuclear Medicine. 2023;64(9):1417-1423. doi:10.2967/jnumed.123.265952

BibTeX
@article{Hope2023,
  author = {Hope, Thomas A and Antonarakis, Emmanuel S and Bodei, Lisa and Calais, Jeremie and Iravani, Amir and Jacene, Heather and Koo, Phillip J and Morgans, Alicia K and Osborne, Joseph R and Tagawa, Scott T and Taplin, Mary-Ellen and Sartor, Oliver and Morris, Michael J},
  title = {SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {9},
  pages = {1417--1423},
  doi = {10.2967/jnumed.123.265952}
}
Kostenlos starten →